➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Dow
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: April 10, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

Docket   Start Trial Date Filed 2014-09-10
Court District Court, D. Delaware Date Terminated 2017-01-30
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Defendant Referred To
Parties NATCO PHARMA LTD.
Patents 6,054,430; 6,342,476; 6,362,161; 6,468,967; 6,852,689; 7,199,098; 7,511,014; 8,232,250; 8,399,413; 8,552,025; 8,642,025; 8,969,302; 9,155,776; 9,533,022; 9,555,023
Attorneys Selena E. Molina
Firms Richards, Layton & Finger, PA
Link to Docket External link to docket
Small Molecule Drugs cited in In Re Copaxone 40 MG Consolidated Cases
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in In Re Copaxone 40 MG Consolidated Cases
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for In Re Copaxone 40 MG Consolidated Cases (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2015-11-02 114 Stipulation invalidity of U.S. Patent Nos. 8,232,250 (“the ’250 patent”), 8,399,413 (“the ’413 patent”), and 8,969,3028,969,302 (“the ’302 patent) (collectively, the “patents-in-suit”), which, like the ’776 patent, are …’776 patent shares a common inventor and specification with the patents-in-suit and each patent is generally… Court: WHEREAS, U.S. Patent No. 9,155,776 (“the ’776 patent”) issued on October 13, 2015 and…that the patents involve similar subject matter, amending the pleadings to include the ’776 patent would External link to document
2015-11-09 116 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,232,250; 8,399,413; 8,969,302…2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. Delaware External link to document
2015-11-19 127 Notice of Service Defendants' Proposed Claim Constructions for U.S. Patent No. 9,155,776 filed by Mylan Inc., Mylan Pharmaceuticals…2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. Delaware External link to document
2015-12-03 130 Notice of Service Joint Invalidity Contentions Regarding U.S. Patent No. 9,155,776 B2 filed by Momenta Pharmaceuticals Inc.…2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. Delaware External link to document
2015-12-17 139 Claim Construction Opening Brief CONSTRUCTION OPENING BRIEF Regarding U.S. Patent No. 9,155,776 filed by Momenta Pharmaceuticals Inc., Sandoz…2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. Delaware External link to document
2015-02-05 17 Status Report of United States Patent No. 8,232,250 (“the ’250 patent”) and United States Patent No. 8,399,413 (“the…involving the infringement of Teva’s U.S. Patent Nos. 8,232,250 and 8,399,413—namely, Civil Action Nos.…more claims of the patents-in-suit patent; and (c) whether the claims of the patents-in-suit are invalid… and Service These patent infringement suits arise under the Patent Laws of the United States,…“the ’413 patent”). The ’250 and ’413 patents are listed in FDA publication “Approved Drug Products with External link to document
2016-02-18 207 Joint Invalidity Contentions Regarding U.S. Patent No. 9,155,776 B2 filed by Mylan Inc., Mylan Pharmaceuticals…2014 31 January 2017 1:14-cv-01171 830 Patent Defendant District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKesson
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.